U.s. fda grants orphan drug designation (odd) for quilience(r) (mazindol er) for the treatment of idiopathic hypersomnia (ih)

Odd for ih in the u.s. follows july 2022 grant of odd for treatment of ih in europe currently only 1 drug approved in the united states to treat ih while no drugs are currently approved in europe for ih high unmet medical need in this rare indication zurich, switzerland / accesswire / november 2, 2022 / nls pharmaceutics ltd. (nasdaq:nlsp, nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that it has received orphan drug designation ("odd") from the fda in the united states for mazindol, the active ingredient in its lead product candidate, quilience® (mazindol er) for the treatment of idiopathic hypersomnia ("ih").
NLSP Ratings Summary
NLSP Quant Ranking